Stock comparison
Eton Pharmaceuticals
IDEXX Laboratories
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ETON
Eton Pharmaceuticals
Market cap
$892.72M
Sector
Healthcare
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ETON | IDXX | Winner |
|---|---|---|---|
| Warren Buffett | 17F | 75B | IDXX |
| Benjamin Graham | 44D | 80A | IDXX |
| Philip Fisher | 40D | 75B | IDXX |
| Peter Lynch | 46D | 71B | IDXX |
| Joel Greenblatt | 0F | 83C | IDXX |
| Charlie Munger | 22F | 87A | IDXX |
| Terry Smith | 22F | 84A | IDXX |
Side-by-side metrics
| Metric | ETON | IDXX |
|---|---|---|
| Market cap | $892.72M | $44.12B |
| P/E (TTM) | - | 39.0x |
| EV/EBIT | 11026.8x | 31.6x |
| ROIC (TTM) | -1.35% | 40.66% |
| Gross margin | 53.46% | 62.05% |
| Net margin | -5.75% | 24.63% |
| Revenue CAGR 5y | 38.33% | 7.56% |
| EPS CAGR 5y | - | 10.79% |
| Debt / Equity | 0.4x | 0.7x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ETON leads on
- P/E (TTM)-vs 39.0x+122%
- Revenue CAGR 5y38.33%vs 7.56%+80%
- Debt / Equity0.4xvs 0.7x+49%
IDXX leads on
- Net margin24.63%vs -5.75%+123%
- ROIC (TTM)40.66%vs -1.35%+103%
- EV/EBIT31.6xvs 11026.8x+100%
- Market cap$44.12Bvs $892.72M+98%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.